Clinical review: Topical ophthalmic use of cyclosporin A

Ocular Immunology and Inflammation

Volumn 18, Issue 5, 2010, Pages 352-361

  Utine, Canan Asli ^a,b   Stern, Michael ^c   Akpek, Esen K ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b YEDITEPE UNIVERSITY   (Turkey)

^c ALLERGAN INC   (United States)

Author keywords

Atopic keratoconjunctivitis; Blepharitis; Cyclosporine A; Dry eye syndrome; Vernal keratoconjunctivitis

Indexed keywords

ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; ANTIINFLAMMATORY AGENT; ARTIFICIAL TEAR; CORTICOSTEROID; CYCLOSPORIN A; DEXAMETHASONE; DEXAMETHASONE PLUS TOBRAMYCIN; ERYTHROMYCIN; EYE DROPS; METHYLPREDNISOLONE; MITOMYCIN C; PAPILOCK MINI; STEROID; UNCLASSIFIED DRUG; WATER OIL CREAM;

ACUTE GRAFT REJECTION; ATOPIC KERATOCONJUNCTIVITIS; BLEPHARITIS; BLURRED VISION; BURNING SENSATION; CLINICAL TRIAL; COGAN SYNDROME; CONJUNCTIVITIS; CORNEA RODENT ULCER; CORNEA TRANSPLANTATION; CORNEA ULCER; CORNEAL EPITHELIOPATHY; DIFFUSE LAMELLAR KERATITIS; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG EXCRETION; DRUG INTERMITTENT THERAPY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY EYE; EYE DISCHARGE; EYE DISEASE; EYE PAIN; EYE REDNESS; EYELID MACERATION; GRAFT VERSUS HOST REACTION; HERPES SIMPLEX KERATITIS; HUMAN; KERATOCONJUNCTIVITIS; KERATOPATHY; LICHEN PLANUS; NEUROTROPHIC KERATOPATHY; NONHUMAN; OCULAR MYOSITIS; OCULAR ROSACEA; POSTERIOR BLEPHARITIS; PUNCTATE KERATITIS; REVIEW; ROSACEA; SARCOIDOSIS; SCLERITIS; STINGING; TOPICAL TREATMENT; VERNAL CONJUNCTIVITIS;

ACUTE DISEASE; BLEPHARITIS; CONJUNCTIVAL DISEASES; CONJUNCTIVITIS, ALLERGIC; CORNEAL TRANSPLANTATION; CYCLOSPORINE; DRY EYE SYNDROMES; EMULSIONS; EYE DISEASES; GRAFT REJECTION; GRAFT VS HOST DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; OPHTHALMIC SOLUTIONS; ROSACEA;

EID: 77956856356     PISSN: 09273948     EISSN: 17445078     Source Type: Journal    
DOI: 10.3109/09273948.2010.498657     Document Type: Review

References (152)

1. De Smet MD, Nussenblat RB. Clinical use of cyclosporine in ocular disease. Int Ophthalmol Clin. 1993;33:31-45.
2. Liu J. FK506 and cyclosporin, molecular probes for studying intracellular signal transduction. Immunol Today. 1993;14:290-295. (Pubitemid 23186993)
3. Nussenblat RB, Palestine AG. Cyclosporine: immunology, pharmacology and therapeutic uses. Surv Ophthalmol. 1986;31:159-169
4. Donnenfeld E, Pflugfelder SC. Topical ophthalmic cyclosporine: pharmacology and clinical uses. Surv Ophthalmol. 2009;54:321-338.
5. Foulks G. Topical cyclosporine for treatment of ocular surface disease. Int Ophthalmol Clin. 2006;46:105-122
6. Kashani S, Mearza AA. Uses and safety profile of cyclosporin in ophthalmology. Expert Opin. Drug Saf. 2008;7:79-89.
7. Borel JF, Feurer C, Magnee C, et al. Effects of the new antilymphocytic peptide cyclosporin A in animals. Immunology. 1977;32:1017-1025.
8. Borel JF, Feurer C, Gubler HU, et al. Biological effects of cyclosporin A: a new antilymphocytic agent. Agents Actions. 1976;6:468-475.
9. Calne RY, White DJ, Thiru S, et al. Cyclosporin A in patients receiving renal allografts from cadaver donors. Lancet. 1978;2:1323-1327.
10. Belin MW, Bouchard CS, Phillips TM. Update on topical cyclosporin A: background, immunology, and pharmacology. Cornea. 1990;9:184-195.
11. Williams DL. A comparative approach to topical cyclosporin therapy. Eye. 1997;11:453-464.
12. Coster DJ, Shepherd WF, Fook TC, et al. Prolonged survival of corneal allografts in rabbits treated with cyclosporin A. Lancet. 1979;2, 688-689.
13. Hunter PA, Wilhelmus KR, Rice NS, et al. Cyclosporin A applied topically to the recipient eye inhibits corneal graft rejection. Clin Exp Immunol. 1981;45:173-177.
14. Hoffmann F, Wiederholt M. [Local treatment of corneal transplants in the human with cyclosporin A.] Klin Monatsbl Augenheilkd. 1985;187:92-96. (Pubitemid 15002386)
15. Holland EJ, Olsen TW, Ketcham JM, et al. Topical cyclosporin A in the treatment of anterior segment inflammatory disease. Cornea. 1993;12:413-419.
16. Gunduz K, Ozden O. Therapeutic use of topical cyclosporine. Ann Ophthalmol. 1993;25:182-186.
17. Tang-Liu DD, Acheampong A. Ocular pharmacokinetics and safety of ciclosporin, a novel topical treatment for dry eye. Clin Pharmacokinet. 2005;44:247-261.
18. Bettelman E, Pleyer U. Immunomodulatory therapy in ophthalmology-is there a place for topical application? Ophthalmologica. 2004;218:359-367.
19. Reidy JJ, Gebhardt BM, Kaufman HE. The collagen shield: a new vehicle for delivery of cyclosporin A to the eye. Cornea. 1990;9:196-199.
20. Kanai A, Alba RM, Takano T, et al. The effect on the cornea of alpha cyclodextrin vehicle for cyclosporine eye drops. Transplant Proc. 1989;21: 3150-3152. (Pubitemid 19124695)
21. Acheampong AA, Shackleton M, Tang-Liu DD, et al. Distribution of cyclosporin A in ocular tissues after topical administration to albino rabbits and beagle dogs. Curr Eye Res. 1999;18:91-103.
22. Sall K, Stevenson OD, Mundorf TK, et al. CsA Phase 3 Study Group. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. Ophthalmology. 2000;107:631-639.
23. Small DS, Acheampong A, Reis B, et al. Blood concentrations of cyclosporin a during long-term treatment with cyclosporin a ophthalmic emulsions in patients with moderate to severe dry eye disease. J Ocul Pharmacol Ther. 2002;18:411-418.
24. Stevenson D, Tauber J, Reis BL. Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The Cyclosporin A Phase 2 Study Group. Ophthalmology. 2000;107:967-974.
25. Gunduz K, Ozdemir O. Topical cyclosporin treatment of keratoconjunctivitis sicca in secondary Sjogrens syndrome. Acta Ophthalmol (Copenh). 1994;72: 438-442.
26. Hingorani M, Moodaley L, Calder VL, et al. A randomized, placebo-controlled trial of topical cyclosporin A in steroid-dependent atopic keratoconjunctivitis. Ophthalmology. 1998;105: 1715-1720.
27. Pflugfelder SC. Antiinflammatory therapy for dry eye. Am J Ophthalmol. 2004;137:337-342.
28. Baudouin C. The pathology of dry eye. Surv Ophthalmol. 2001;45:211-220.
29. Johnson ME, Murphy PJ. Changes in the tear film and ocular surface from dry eye syndrome. Prog Retin Eye Res. 2004;23:449-474.
30. The definition and classification of dry eye disease: Report of The Definition and Classification Subcommittee of The International Dry Eye Workshop (2007). Ocul Surf. 2007; 5(2):75-92.
31. Stern ME, Gao J, Siemasko KF, et al. The role of the lacrimal functional unit in the pathophysiology of dry eye. Exp Eye Res. 2004;78:409-416.
32. Sullivan DA, Wickham LA, Rocha EM, et al. Androgens and dry eye in Sjogrens syndrome. Ann N Y Acad Sci. 1999;876:312-324.
33. Laibovitz RA, Solch S, Andriano K, et al. Pilot trial of cyclosporin 1% ophthalmic ointment in the treatment of keratoconjunctivitis sicca. Cornea. 1993;12:315-323.
34. Power WJ, Mullaney P, Farrell M, et al. Effect of topical cyclosporin A on conjunctival T cells in patients with secondary Sjogrens syndrome. Cornea. 1993;12:507-511.
35. Kunert KS, Tisdale AS, Gipson IK. Goblet cell numbers and epithelial proliferation in the conjunctiva of patients with dry eye syndrome treated with cyclosporin. Arch Ophthalmol. 2002;120:330-337.
36. Kunert KS, Tisdale AS, Stern ME, et al. Analysis of topical cyclosporine treatment of patients with dry eye syndrome: effect on conjunctival lymphocytes. Arch Ophthalmol. 2000;118:1489-1496.
37. Turner K, Pflugfelder SC, Ji Z, et al. Interleukin-6 levels in the conjunctival epithelium of patients with dry eye disease treated with cyclosporin ophthalmic emulsion. Cornea. 2000;19:492-496.
38. Roberts CW, Elie ER. Dry eye symptoms following cataract surgery. Insight. 2007;32:14-21.
39. Salib GM, McDonald MB, Smolek M. Safety and efficacy of cyclosporine 0.05% drops versus unpreserved artificial tears in dry-eye patients having laser in situ keratomileusis. J Cataract Refract Surg. 2006;32:772-778.
40. Byun YJ, Kim TI, Kwon SM, et al. Efficacy of combined 0.05% cyclosporine and 1% methylprednisolone treatment for chronic dry eye. Cornea. 2009 Aug 31 [Epub ahead of print]
41. Dastjerdi MH, Hamrah P, Dana R. High-frequency topical cyclosporine 0.05% in the treatment of severe dry eye refractory to twice-daily regimen. Cornea. 2009;28:1091-1096.
42. Gupta A, Sadeghi PB, Akpek EK. Occult thyroid eye disease in patients presenting with dry eye symptoms. Am J Ophthalmol. 2009;147:919-923.
43. Cheung J, Sharma S. Ophthaproblem: blepharitis. Can Fam Physician. 2000;46:2393-2400.
44. McCulley JP, Shine WE. Changing concepts in the diagnosis and management of blepharitis. Cornea. 2000;19:650-658.
45. Kocak-Altintas AG, Kocak-Midillioglu I, Gul U, et al. Impression cytology and ocular characteristics in ocular rosacea. Eur J Ophthalmol. 2003;13:351-359.
46. Fukushima A, Ozaki A, Fukata K, et al. Age-specific recognition, activation, and effector function of T-cells in the conjunctiva with experimental immunemediated blepharoconjunctivitis. Invest Ophthalmol Vis Sci. 2003;44:4366-4374.
47. Carreras I, Carreras B, McGrath L, et al. Activated T-cells in an animal model of allergic conjunctivitis. Br J Ophthalmol. 1993;77:509-514.
48. Magone MT, Chan CC, Rizzo LV, et al. A novel murine model of allergic conjunctivitis. Clin Immunol Immunopathol. 1998;87:75-84.
49. Liu G, Keane-Myers A, Miyazaki D, et al. Molecular and cellular aspects of allergic conjunctivitis. Chem Immunol. 1999;73:39-58.
50. Rubin M, Rao SN. Efficacy of topical cyclosporin 0.05% in the treatment of posterior blepharitis. J Ocul Pharmacol Ther. 2006;22:47-53.
51. Perry HD, Doshi-Carnevale S, Donnenfeld ED, et al. Efficacy of commercially available topical cyclosporine a 0.05% in the treatment of meibomian gland dysfunction. Cornea. 2006;25:171-175.
52. Akpek EK, Merchant A, Pinar V, et al. Ocular rosacea: patient characteristics and follow-up. Ophthalmology. 1997;104:1863-1867.
53. Doan S, Gabison E, Gatinel D, et al. Topical cyclosporine A in severe steroid-dependent childhood phlyctenular keratoconjunctivitis. Am J Ophthalmol. 2006;141:62-66.
54. Schechter BA, Katz RS, Friedman LS. Efficacy of topical cyclosporine for the treatment of ocular rosacea. Adv Ther. 2009;26:1-9.
55. Allansmith MR. Vernal conjunctivitis. In: Duane TD, Jaeger EA, eds. Clinical Ophthalmology, rev ended. Philadelphia, PA: Harper & Row; 1986: 1.
56. Collum LM. Vernal keratoconjunctivitis. Acta Ophthalmol Scand Suppl. 1999: 77: 14-16.
57. Ukponmwan CU. Vernal keratoconjunctivitis in Nigerians: 109 consecutive cases. Trop Doct. 2003;33:242-245.
58. Tabbara KF, Ross-Degnan D. Blindness in Saudi Arabia. JAMA. 1986;255:3378-3384.
59. Herse P, Gothwal VK. Survey of visual impairment in an Indian tertiary eye hospital. Indian J Ophthalmol. 1997;45:189-193.
60. Abu el-Asrar AM, Van den Oord JJ, Geboes K, et al. Immunopathological study of vernal keratoconjunctivitis. Graefes Arch Clin Exp Ophthalmol. 1989;227:374-379.
61. el-Asrar AM, Tabbara KF, Geboes K, et al. An immunohistochemical study of topical cyclosporin in vernal keratoconjunctivitis. Am J Ophthalmol. 1996;121:156-161.
62. El Hennawi M. A double blind placebo controlled group comparative study of ophthalmic sodium cromoglycate and nedocromil sodium in the treatment of vernal keratoconjunctivitis. Br J Ophthalmol. 1994;78:365-369.
63. Bonini S, Barney NP, Schiavone M, et al. Effectiveness of nedocromil sodium 2% eyedrops on clinical symptoms and tear fluid cytology of patients with vernal conjunctivitis. Eye. 1992;6:648-652.
64. Foster CS. Evaluation of cromolyn sodium in the treatment of vernal keratoconjunctivitis. Ophthalmology. 1988;95: 194-201.
65. Resnikoff S, Cornand G, Filliard G, et al. Limbal vernal keratoconjunctivitis in the tropics. Rev Int Trach Pathol Ocul Trop Subtrop Sante Publique. 1988;65:21-72.
66. Baryishak YR, Zavaro A, Monselise M, et al. Vernal keratoconjunctivitis in an Israeli group of patients and its treatment with sodium cromoglycate. Br J Ophthalmol. 1982;66:118-122.
67. Abiose A. Paediatric ophthalmic problems in Nigeria. J Trop Pediatr. 1985;31:30-35.
68. Tabbara KF. Ocular complications of vernal keratoconjunctivitis. Can J Ophthalmol. 1999;34:88-92.
69. Akpek EK, Hasiripi H, Christen WG, et al. A randomized trial of low-dose, topical mitomycin-C in the treatment of severe vernal keratoconjunctivitis. Ophthalmology. 2000;107:263-269.
70. BenEzra D, Peer J, Brodsky M, et al. Cyclosporin eyedrops for the treatment of severe vernal keratoconjunctivitis. Am J Ophthalmol. 1986;101:278-282.
71. Secchi AG, Tognon MS, Leonardi A. Topical use of cyclosporin in the treatment of vernal keratoconjunctivitis. Am J Ophthalmol. 1990;110:641-645.
72. Bleik JH, Tabbara KF. Topical cyclosporin in vernal keratoconjunctivitis. Ophthalmology. 1991;98:1679-1684.
73. Avunduk AM, Avunduk MC, Erdol H, et al. Cyclosporin effects on clinical findings and impression cytology specimens in severe vernal keratoconjunctivitis. Ophthalmologica. 2001;215:290-293.
74. Pucci N, Novembre E, Cianferoni A, et al. Efficacy and safety of cyclosporine eyedrops in vernal keratoconjunctivitis. Ann Allergy Asthma Immunol. 2002;89:298-303.
75. Cetinkaya A, Akova YA, Dursun D, et al. Topical cyclosporin in the management of shield ulcers. Cornea. 2004;23:194-200.
76. Spadavecchia L, Fanelli P, Tesse R, et al. Efficacy of 1.25% and 1% topical cyclosporine in the treatment of severe vernal keratoconjunctivitis in childhood. Pediatr Allergy Immunol. 2006;17:527-532.
77. Garrity JA, Liesegang TJ. Ocular complications of atopic dermatitis. Can J Ophthalmol. 1984;19:19-24.
78. Power WJ, Tugal-Tutkun I, Foster CS. Long-term follow-up of patients with atopic keratoconjunctivitis. Ophthalmology.1998;105:637-642.
79. Belfort R, Marbeck P, Hsu CC, et al. Epidemiological study of 134 subjects with allergic conjunctivitis. Acta Ophthalmol Scand Suppl. 2000;230:38-40.
80. Tuft SJ, Kemeny DM, Dart JK, et al. Clinical features of atopic keratoconjunctivitis. Ophthalmology. 1991;98:150-158.
81. Foster CS, Rice BA, Dutt JE. Immunopathology of atopic keratoconjunctivitis. Ophthalmology. 1991;98:1190-1196.
82. Metz DP, Hingorani M, Calder VL, et al. T-cell cytokines in chronic allergic eye disease. J Allergy Clin Immunol. 1997;100:817-824.
83. Calder VL, Jolly G, Hingorani M, et al. Cytokine production and mRNA expression by conjunctival T-cell lines in chronic allergic eye disease. Clin Exp Allergy. 1999;29:1214-1222.
84. Foster CS, Calonge M. Atopic keratoconjunctivitis. Ophthalmology. 1990;97:992-1000.
85. Hingorani M, Moodaley L, Calder VL, et al. A randomized, placebo controlled trial of topical cyclosporin A in steroid-dependent atopic keratoconjunctivitis. Ophthalmology. 1998;105:1715-1720.
86. Akpek EK, Dart JK, Watson S, et al. A randomized trial of topical cyclosporine 0.05% in topical steroid-resistant atopic keratoconjunctivitis. Ophthalmology. 2004;111:476-482. (Pubitemid 38293102)
87. Tomida I, Schlote T, Brauning J, et al. [Cyclosporin A 2% eyedrops in therapy of atopic and vernal keratoconjunctivitis.] Ophthalmologe. 2002;99:761-767.
88. Daniell M, Constantinou M, Vu HT, et al. Randomised controlled trial of topical cyclosporin A in steroid dependent allergic conjunctivitis. Br J Ophthalmol. 2006;90: 461-464.
89. Hingorani M, Calder VL, Buckley RJ, et al. The immunomodulatory effect of topical cyclosporin A in atopic keratoconjunctivitis. Invest Ophthalmol Vis Sci. 1999;40:392-399.
90. Ebihara N, Ohashi Y, Uchio E, et al. A large prospective observational study of novel cyclosporine 0.1% aqueous ophthalmic solution in the treatment of severe allergic conjunctivitis. J Ocul Pharmacol Ther. 2009;25:365-372.
91. Williams KA, Muehlberg SM, Barlett CM, et al. Report from the Australian Corneal Graft Registry. Adelaide: Flinders University Press; 2007.
92. Arentsen JJ. Corneal transplant allograft reaction: possible predisposing factors. Trans Am Ophthalmol Soc. 1983;81:361-402.
93. Hudde T, Minassian DC, Larkin DFP. Randomised controlled trial of corticosteroid regimens in endothelial corneal allograft rejection. Br J Ophthalmol. 1999;83:1348-1352.
94. Hill JC, Maske R, Watson P. Corticosteroids in corneal graft rejection: oral versus single pulse therapy. Ophthalmology. 1991;98:329-333.
95. Randleman JB, Stulting RD. Prevention and treatment of corneal graft rejection: current practice patterns (2004). Cornea. 2006;25:286-290.
96. Perry HD, Donnenfeld ED, Acheampong A, et al. Topical cyclosporine A in the management of postkeratoplasty glaucoma and corticosteroid-induced ocular hypertension (CIOH) and the penetration of topical 0.5% cyclosporine A into the cornea and anterior chamber. CLAO J. 1998;24:159-165.
97. Price MO, Price FW. Efficacy of topical cyclosporine 0.05% for prevention of cornea transplant rejection episodes. Ophthalmology. 2006;113:1785-1790.
98. Poon A, Constantinou M, Lamoureux E, et al. Topical cyclosporin A in the treatment of acute graft rejection: a randomized controlled trial. Clin Experiment Ophthalmol. 2008;36:415-421.
99. Lelli GJ, Musch DC, Gupta A, et al. Ophthalmic cyclosporine use in ocular GvHD. Cornea. 2006;25:635-638.
100. Ogawa Y, Kuwana M. Dry eye as a major complication associated with chronic graft-versus-host disease after hematopoietic stem cell transplantation. Cornea. 2003;22:S19-S27.
101. Franklin RM, Kenyon KR, Tutschka PJ, et al. Ocular manifestations of graft-vs-host disease. Ophthalmology. 1983;90:4-13.
102. Ogawa Y, Okamoto S, Wakui M, et al. Dry eye after haematopoietic stem cell transplantation. Br J Ophthalmol. 1999;83:1125-1130.
103. Hirst LW, Jabs DA, Tutschka PJ, et al. The eye in bone marrow transplantation, I: clinical study. Arch Ophthalmol. 1983;101:580-584.
104. Ogawa Y, Yamazaki K, Kuwana M, et al. A significant role of stromal fibroblasts in rapidly progressive dry eye in patients with chronic GvHD. Invest Ophthalmol Vis Sci. 2001;42:111-119.
105. Ogawa Y, Kuwana M, Yamazaki K, et al. Periductal area as the primary site for T-cell activation in lacrimal gland chronic graft-versus-host disease. Invest Ophthalmol Vis Sci. 2003;44:1888-1896.
106. Rao SN, Rao RD. Efficacy of topical cyclosporine. 05% in the treatment of dry eye associated with graft versus host disease. Cornea. 2006;25:674-678.
107. Wang Y, Ogawa Y, Dogru M, et al. Ocular surface and tear functions after topical cyclosporine treatment in dry eye patients with chronic graft-versus-host disease. Bone Marrow Transplant. 2008;41:293-302.
108. Foster CS, Forstot SL, Wilson LA. Mortality rate in rheumatoid arthritis patients developing necrotizing scleritis or peripheral ulcerative keratitis: effects of systemic immunosuppression. Ophthalmology. 1984;91:1253-1263.
109. Pfister RR, Murphy GE. Corneal ulceration and perforation associated with Sjogrens syndrome. Arch Ophthalmol. 1980;98:89-94.
110. Zierhut M, Thiel HJ, Weidle EG, et al. Topical treatment of severe corneal ulcers with cyclosporin A. Graefes Arch Clin Exp Ophthalmol. 1989;227:30-35.
111. Kervick GN, Pflugfelder SC, Haimovici R, et al. Paracentral rheumatoid corneal ulceration: clinical features and cyclosporin therapy. Ophthalmology. 1992;99:80-88.
112. Gottsch JD, Akpek EK. Topical cyclosporin stimulates neovascularization in resolving sterile rheumatoid central corneal ulcers. Trans Am Ophthalmol Soc. 2000;98:81-87.
113. Liegner JT, Yee RW, Wild JH. Topical cyclosporin therapy for ulcerative keratitis associated with rheumatoid arthritis. Am J Ophthalmol. 1990;109:610-612.
114. Thygeson P. Superficial punctate keratitis. JAMA. 1950;144:1544-1549.
115. Nagra PK, Rapuano CJ, Cohen EJ, et al. Thygesons superficial punctuate keratitis: ten years experience. Ophthalmology. 2004;111:34-37.
116. Hardten DR, Doughman DJ, Holland EJ, et al. Persistent superficial punctuate keratitis after resolution of chlamydial follicular conjunctivitis. Cornea. 1992;11:360-363.
117. Reinhard T, Roggendorf M, Fengler I, et al. PCR for varicella zoster virus genome negative in corneal epithelial cells of patients with Thygesons superficial punctate keratitis. Eye. 2004;18:304-305.
118. Goldberg DB, Schanzlin DJ, Brown SI. Management of Thygesons superficial punctate keratitis. Am J Ophthalmol. 1980;89:22-24.
119. Forstot SL, Binder PS. Treatment of Thygesons superficial punctuate keratopathy with soft contact lenses. Am J Ophthalmol. 1979;88:186-189.
120. Reinhard T, Sundmacher R. [Local cyclosporin A therapy in Thygeson superficial punctate keratitis-a pilot study.] Klin Monatsbl Augenheilkd. 1996;209:224-227.
121. Reinhard T, Sundmacher R. Topical cyclosporin A in Thygesons superficial punctate keratitis. Graefes Arch Clin Exp Ophthalmol. 1999;237:109-112.
122. Del Castillo JM, Del Castillo JB, Garcia-Sanchez J. Effect of topical cyclosporine A on Thygesons superficial punctate keratitis. Doc Ophthalmol. 1996-1997;93:193-198.
123. Schuster V, Seregard S. Ligneous conjunctivitis. Surv Ophthalmol. 2003;48:369-388.
124. Hidayat AA, Riddle PJ. Ligneous conjunctivitis: a clinicopathologic study of 17 cases. Ophthalmology. 1987;94: 949-959.
125. Watts P, Suresh P, Mezer E, et al. Effective treatment of ligneous conjunctivitis with topical plasminogen. Am J Ophthalmol. 2002;133:451-455.
126. Holland EJ, Chan CC, Kuwabara T, et al. Immunohistologic findings and results of treatment with cyclosporin in ligneous conjunctivitis. Am J Ophthalmol. 1989;107: 160-166.
127. Rao SK, Biswas J, Rajagopal R, et al. Ligneous conjunctivitis: a clinicopathologic study of 3 cases. Int Ophthalmol. 1998-1999;22:201-206.
128. Rubin BI, Holland EJ, de Smet MD, et al. Response of reactivated ligneous conjunctivitis to topical cyclosporin. Am J Ophthalmol. 1991;112:95-96.
129. Boyd AS, Neldner KH. Lichen planus. J Am Acad Dermatol. 1991;25:593-619.
130. Thorne JE, Jabs DA, Nikolskaia OV, et al. Lichen planus and cicatrizing conjunctivitis: characterization of five cases. Am J Ophthalmol. 2003;136:239-243.
131. Neumann R, Dutt CJ, Foster CS. Immunohistopathologic features and therapy of conjunctival lichen planus. Am J Ophthalmol. 1993;115:494-500.
132. Oliver GF, Winkelmann RK. Treatment of lichen planus. Drugs. 1993;45:56-65.
133. Levell NJ, Munro CS, Marks JM. Severe lichen planus clears with very low dose cyclosporin. Br J Dermatol. 1992;127: 66-67.
134. Crompton DO. Immuno-suppressive drug treatment of keratitis sicca, including an example of lichen planus of the conjunctiva. Aust N Z J Surg. 1968;38:143-146.
135. Leonardi A, DeFranchis G, Fregona IA, et al. Effects of cyclosporin A on human conjunctival fibroblasts. Arch Ophthalmol. 2001;119:1512-1517.
136. Rhee MK, Mootha VV. Bilateral keratoconjunctivitis associated with lichen planus. Cornea. 2004;23:100-105.
137. Pakravan M, Klesert T, Akpek EK. Isolated lichen planus of the conjunctiva. Br J Ophthalmol. 2006;90:1325-1326.
138. Theodore FH. Further observations on superior limbic keratoconjunctivitis. Trans Am Acad Ophthalmol Otolaryngol. 1967;71:341-351.
139. Cher I. Superior limbic keratoconjunctivitis: multifactorial mechanical pathogenesis. Clin Exp Ophthalmol. 2000;28: 181-184.
140. Perry HD, Doshi-Carnevale S, Donnenfeld ED, et al. Topical cyclosporin A 0.5% as a possible new treatment for superior limbic keratoconjunctivitis. Ophthalmology. 2003;110:1578-1581.
141. Gunduz K, Ozdemir O. Topical cyclosporin as an adjunct to topical acyclovir treatment in herpetic stromal keratitis. Ophthalmic Res. 1997;29:405-408.
142. Heiligenhaus A, Steuhl KP. Treatment of HSV-1 stromal keratitis with topical cyclosporin A: a pilot study. Graefes Arch Clin Exp Ophthalmol. 1999;237:435-438.
143. Rao SN. Treatment of herpes simplex virus stromal keratitis unresponsive to topical prednisolone 1% with topical cyclosporine 0.05%. Am J Ophthalmol. 2006;141:771-772.
144. Reynolds SA, Kabat AG. Therapeutic options for the management of early neurotrophic keratopathy: a case report and review. Optometry. 2006;77:503-507.
145. Zhao JC, Jin XY. Immunological analysis and treatment of Moorens ulcer with cyclosporin A applied topically. Cornea. 1993;12:481-488.
146. Shimura M, Yasuda K, Fuse N, et al. Effective treatment With topical cyclosporin A of a patient with Cogan syndrome. Ophthalmologica. 2000;214:429-432.
147. Akpek EK, Ilhan-Sarac O, Green WR. Topical cyclosporin in the treatment of chronic sarcoidosis of the conjunctiva. Arch Ophthalmol. 2003;121:1333-1335.
148. McCoombes JA, Hirst LW, Green WR. Use of topical cyclosporin for conjunctival manifestations of actinic prurigo. Am J Ophthalmol. 2000;130:830-831.
149. Derse M, Wannke E, Payer H, et al. [Successful topical cyclosporin A in the therapy of progressive vascularising keratitis in keratitis-ichthyosis- deafness (KID) syndrome (Senter syndrome).] Klin Monatsbl Augenheilkd. 2002;219:383-386.
150. Chung MS, Pepose JS, El-Agha MS, et al. Confocal microscopic findings in a case of delayed-onset bilateral diffuse lamellar keratitis after laser in situ keratomileusis. J Cataract Refract Surg. 2002;28:1467-1470.
151. Touzeau O, Borderie V, Razavi S, et al. [Use of topical cyclosporin in microcrystalline keratopathy due to streptococcus.] J Fr Ophtalmol. 1999;22:662-665.
152. Gumus K, Mirza E, Cavanagh HD, et al. Topical cyclosporine A as a steroid-sparing agent in steroid-dependent idiopathic ocular myositis with scleritis: a case report and review of literature. Eye & Contact Lens. 2009;5:275-278.